HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Saburo Sone Selected Research

N- hydroxy- 5- ethoxymethyloxy- 2- methyl- 4- (4- phenoxybenzoyl)aminopentanamide

3/2003A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice.
10/2002Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Saburo Sone Research Topics

Disease

54Neoplasms (Cancer)
06/2019 - 02/2002
34Lung Neoplasms (Lung Cancer)
06/2019 - 02/2002
25Neoplasm Metastasis (Metastasis)
01/2014 - 07/2002
15Small Cell Lung Carcinoma (Small Cell Lung Cancer)
03/2013 - 02/2002
15Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2012 - 07/2002
10Pleural Effusion (Pleural Effusions)
08/2012 - 02/2002
8Rheumatoid Arthritis
03/2014 - 09/2002
8Inflammation (Inflammations)
12/2013 - 02/2003
8Malignant Mesothelioma
06/2013 - 01/2006
7Pulmonary Fibrosis (Fibrosing Alveolitis)
10/2013 - 06/2003
5Asthma (Bronchial Asthma)
12/2013 - 02/2002
5Fibrosis (Cirrhosis)
03/2012 - 02/2005
5Adenocarcinoma of Lung
11/2008 - 07/2002
5Malignant Pleural Effusion
02/2007 - 02/2002
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
09/2012 - 01/2006
3Body Weight (Weight, Body)
01/2013 - 03/2003
3Idiopathic Pulmonary Fibrosis
03/2012 - 02/2005
3Pneumonia (Pneumonitis)
01/2012 - 06/2003
3Mesothelioma
10/2011 - 10/2007
3Neoplasm Micrometastasis
07/2011 - 03/2003
3Adenocarcinoma
07/2010 - 01/2006
3Systemic Lupus Erythematosus (Libman-Sacks Disease)
02/2008 - 11/2003
2Respiratory Hypersensitivity
12/2013 - 01/2009
2Radiation Pneumonitis
07/2010 - 06/2003
2Multiple Myeloma
06/2009 - 01/2009
2Chronic Hepatitis C
12/2007 - 02/2007
2Infections
06/2007 - 02/2007

Drug/Important Bio-Agent (IBA)

16Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2012 - 03/2002
15Tyrosine Kinase InhibitorsIBA
09/2012 - 05/2003
15ErbB Receptors (EGF Receptor)IBA
09/2012 - 01/2003
11CytokinesIBA
03/2014 - 02/2002
11Gefitinib (Iressa)FDA Link
09/2012 - 05/2003
8Phosphotransferases (Kinase)IBA
09/2012 - 01/2004
7Bleomycin (Blenoxane)FDA LinkGeneric
10/2013 - 02/2005
6Erlotinib Hydrochloride (CP 358,774)FDA Link
03/2012 - 11/2008
5Parathyroid Hormone-Related ProteinIBA
01/2014 - 02/2004
5Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2006 - 03/2002
5Proteins (Proteins, Gene)FDA Link
08/2005 - 03/2003
4Pharmaceutical PreparationsIBA
06/2019 - 03/2003
4indium-bleomycinIBA
10/2013 - 02/2005
4Neutralizing AntibodiesIBA
09/2012 - 02/2004
4Tyrosine (L-Tyrosine)FDA Link
07/2011 - 01/2005
4Monoclonal AntibodiesIBA
10/2010 - 06/2003
4Diphosphonates (Bisphosphonates)IBA
01/2009 - 01/2003
3Interleukin-8 (Interleukin 8)IBA
01/2018 - 01/2004
3Thymidine PhosphorylaseIBA
01/2017 - 09/2012
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2014 - 01/2004
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
09/2012 - 01/2006
3Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
08/2012 - 12/2007
3Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
03/2012 - 11/2008
3SteroidsIBA
01/2012 - 02/2003
3Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
09/2011 - 06/2003
3Imatinib Mesylate (Gleevec)FDA Link
09/2011 - 06/2005
3Interferon-betaIBA
06/2009 - 02/2005
3Therapeutic UsesIBA
01/2009 - 12/2005
3YM 529IBA
01/2009 - 01/2003
3vandetanib (ZD6474)IBA
06/2008 - 12/2005
3Transforming Growth Factor beta (TGF-beta)IBA
12/2007 - 01/2005
3Complementary DNA (cDNA)IBA
06/2007 - 05/2003
3src-Family KinasesIBA
09/2006 - 01/2005
3N- (2- chloro- 5- methoxyphenyl)- 6- methoxy- 7- ((1- methyl- 4- piperidinyl) methoxy) 4-quinazolinamineIBA
09/2006 - 01/2005
3Oxygen (Dioxygen)IBA
04/2006 - 07/2002
3CD13 Antigens (Alanine Aminopeptidase)IBA
11/2003 - 02/2002
3Matrix Metalloproteinases (MMPs)IBA
03/2003 - 10/2002
2Indicators and Reagents (Reagents)IBA
06/2019 - 08/2005
2EnzymesIBA
01/2017 - 02/2007
2Cyclin-Dependent Kinase Inhibitor p16IBA
04/2015 - 11/2010
2CC ChemokinesIBA
12/2013 - 12/2003
2orantinib (SU6668)IBA
08/2012 - 09/2011
2Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
01/2012 - 12/2006
2AntibodiesIBA
12/2011 - 01/2009
2AcidsIBA
10/2011 - 03/2010
2Docetaxel (Taxotere)FDA Link
08/2011 - 03/2003
2lenvatinibIBA
07/2011 - 12/2009
2AntigensIBA
06/2009 - 02/2002
2Membrane Proteins (Integral Membrane Proteins)IBA
06/2009 - 01/2009
2Bone Marrow Stromal Antigen 2IBA
06/2009 - 01/2009
2InterferonsIBA
01/2009 - 02/2005
2N- (3,5- bis(trifluoromethyl)phenyl)- 5- chloro- 2- hydroxybenzamideIBA
01/2009 - 05/2006
2Zoledronic Acid (Zometa)FDA Link
01/2009 - 01/2009
2NF-kappa B (NF-kB)IBA
01/2009 - 05/2006
2I-kappa B KinaseIBA
01/2009 - 05/2006
2Bevacizumab (Avastin)FDA Link
01/2009 - 10/2007
2LigandsIBA
11/2008 - 02/2005
2reveromycin AIBA
12/2007 - 12/2005
2Interferon Type IIBA
12/2007 - 02/2007
2Cathepsin GIBA
02/2007 - 12/2006
2Chemotactic FactorsIBA
02/2007 - 02/2002
2anilinoquinazolineIBA
09/2006 - 06/2005
2Cisplatin (Platino)FDA LinkGeneric
03/2006 - 11/2004
2AsbestosIBA
03/2006 - 01/2006
2Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
01/2006 - 12/2005
2Myosins (Myosin)IBA
01/2006 - 09/2002
2Anti-Bacterial Agents (Antibiotics)IBA
12/2005 - 05/2003
2Epidermal Growth Factor (EGF)IBA
12/2005 - 02/2003

Therapy/Procedure

30Therapeutics
06/2019 - 02/2002
9Drug Therapy (Chemotherapy)
08/2011 - 05/2003
4Radiotherapy
01/2011 - 06/2003
4Immunotherapy
06/2009 - 02/2002
3Molecular Targeted Therapy
01/2011 - 06/2010